Results

Total Results: 743 records

Showing results for "continuing".

21. Archived: Final Modeling Report: Breast Cancer: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-modeling-report/breast-cancer-screening-2009
    November 15, 2009 - In all models, biennial screening starting at age 50 years and continuing through ages 74, 79, or 84 … Continuing screening to age 79 years (vs. 69 years) results in a median increase in percentage of mortality … For instance, starting annual screening at age 40 years (vs. 50 years) and continuing annually to age … Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness

22. Recommendation: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-to-prevent-cardiovascular-disease-preventive-medication
    April 26, 2022 - 85 years, modeling data suggested that there is generally little incremental lifetime net benefit in continuing … aspirin use beyond the age of 75 to 80 years. 26 , 27 It is important to note that the net benefit of continuing … who first reach a 10% or greater 10-year CVD risk in their 60s or 70s and may gain more benefit by continuing

23. Individualizing Cancer Screening in Older Adults | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/individualizing-cancer-screening-older-adults
    March 01, 2021 - Older adults' attitudes about continuing cancer screening later in life: a pilot study interviewing residents … of two continuing care communities. 

24. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/-TsBkyewVoFpC7htRmzWJa
    September 03, 2019 - raloxifene, the Mul- tiple Outcomes of Raloxifene Evaluation (MORE) with long-term follow-up in the Continuing … CORE indicates Continuing Outcomes Relevant to Evista; HOT, Hormone replaced therapy Opposed by low-dose … Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women … Siris ES, Harris ST, Eastell R, et al; Continuing Outcomes Relevant to Evista (CORE) Investigators. … Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista

25. Archived: Colorectal Cancer: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening-2008
    October 15, 2008 - Summary Population Recommendation Grade Adults, beginning at age 50 years and continuing … fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults, beginning at age 50 years and continuing … screening, routine colorectal cancer screening is now recommended in adults beginning at age 50 and continuing

26. Archived: Tobacco Use Prevention: Counseling, 1996 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-prevention-counseling-1996
    January 01, 1996 - Smokers who quit smoking before the age of 50 have up to half the risk of dying in the next 15 years that continuing … after age 70. 3 After 10 years of abstinence, the risk of lung cancer is 30-50% lower than that of continuing … 15 years it returns to (or near to) that of persons who have never smoked. 3 , 36 36a Relative to continuing

27. Archived: Chlamydial Infection: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/chlamydial-infection-screening-2007
    June 15, 2007 - For patients at continuing risk, or who are newly at risk: Screen in the 3rd trimester. … For patients at continuing risk, or who are newly at risk: Screen in the 3rd trimester.

28. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/LPaUxRbrTshfsYVVTzenEQ
    April 26, 2022 - years, modeling data sug- gested that there is generally little incremental lifetime net benefit in continuing … aspirin use beyond the age of 75 to 80 years.26,27 It is important to note that the net benefit of continuing … who first reach a 10% or greater 10-year CVD risk in their 60s or 70s and may gain more benefit by continuing

29. Procedure Manual Section 5. Modeling | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual/procedure-manual-section-5-modeling
    July 05, 2017 - The Task Force is continuing to determine a full set of clear criteria, using its past experience with

30. Screening for Overweight in Children and Adolescents: Where Is the Evidence? (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/7K93Ldpe86aLuGS65CPKYp
    July 01, 2005 - reduced self-esteem, poor eating habits, eating disorders, adverse family relations, or the effects of continuing

31. Screening for Hepatitis B Virus Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/gYdxwvAQZ73SApY2Hosz_d
    October 11, 2019 - Women with unknown HBsAg status or with new or continuing risk factors for HBV infection (eg, injection … Women with unknown HBsAg status or with new or continuing risk factors for HBV infection (eg, injection

32. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: USPSTF Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/by8VJVre6h6BmadrGxaFMM
    April 01, 2016 - Initiating aspirin use during ages 50 to 59 years and continuing unless contraindicated by an adverse … Initiating aspirin use during ages 60 to 69 years and continuing unless contraindicated by an adverse … Many comments requested clarification about initiating and continuing aspirin use, especially for persons … focus on initiating aspirin use and enhanced the “Imple- mentation” section to provide guidance on continuing

33. Archived: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction-2013
    September 15, 2013 - with placebo: the Multiple Outcomes of Raloxifene Evaluation study, with long-term follow-up in the Continuing … Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women … Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, et al; Continuing Outcomes Relevant … Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista

34. Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/6hyj7-3s6Qxs-brqhxPVxD
    June 06, 2017 - AND RECOMMENDATIONS TheUSPSTF recommends screening for colorectal cancer starting at age 50years and continuing … and Evidence The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing … Amongolder adultswhohave beenpreviouslyscreenedforcolorectalcancer, there isatbestamod­ erate benefit to continuing … HSgFOBT every year 22 20 23 of 50 and 75 years, with follow-up CT colonography every 5 yb 22 20 24 continuing

35. Archived: Lung Cancer: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening-december-2013
    December 31, 2013 - This model predicts the outcomes of continuing the screening program used in the NLST through age 80 … Current smokers should be informed of their continuing risk for lung cancer and offered cessation treatments … Recent data from the Italian Continuing Observation of Smoking Subjects cohort study of approximately

36. Testimony for the House Energy and Commerce Health Subcommittee Hearing (pdf file)
    www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/tfcongresstestimony%20(3).pdf
    November 30, 2016 - I look forward to continuing to get to know Ruth even better, to understanding more about what’s important

37. Uhtgkzvs Bpnj4 G4Fxuay (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/uhtgkZVs_bpNJ4_G4fXUay
    March 01, 2014 - This model predicts the outcomes of continuing the screening program used in the NLST through age 80 … Current smokers should be informed of their continuing risk for lung cancer and offered cessation treatments … Recent data from the Italian Continuing Observation of Smoking Subjects cohort study of approximately

38. Evidence Summary: Obstructive Sleep Apnea in Adults: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary29/obstructive-sleep-apnea-in-adults-screening
    November 15, 2022 - Share to Facebook Share to X Share to WhatsApp Share to Email Print Evidence Summary Obstructive Sleep Apnea in Adults: Screening November 15, 2022 Recommendations made by the USPSTF are independent of the U.S. government. They should not be con…

39. Screening for Obstructive Sleep Apnea in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/Z6Rfj-qwfoMbuLp-hBmhzS
    May 01, 2021 - Screening for Obstructive Sleep Apnea in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force Screening for Obstructive Sleep Apnea in Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force Cynthia Feltner, MD, MPH; Ina F. Wallace, PhD…

40. Zvvry6Wa4Sgj-Ejb3Brcvy (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/zVVRY6wa4Sgj-EJb3BRcVy
    November 01, 2013 - the MORE (Multiple Outcomes of Raloxifene Eval- uation) study, with long-term follow-up in the CORE (Continuing … Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women … Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, et al; Continuing Outcomes Relevant … Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista